Citi analyst Yigal Nochomovitz lowered the firm’s price target on Krystal Biotech (KRYS) to $166 from $176 and keeps a Neutral rating on the shares after its Q2 earnings miss. The company saw Vyjuvek sales up 9% q/q, though this was tempered by cautionary commentary referencing Q3 US Vyjuvek expected to fall “below Q2”, the analyst tells investors in a research note. Citi adds however that launches in Europe and Japan are important upside levers for Krystal that could eventually earn a stock recommendation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Krystal Biotech price target lowered to $182 from $192 at BofA
- Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating
- Video: Why These Stocks Are Moving Today
- Krystal Biotech reports Q2 EPS $1.29, consensus $1.44